Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Read more
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation Read more
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors Read more
Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets Read more
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases Read more
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products Read more
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines Read more